Literature DB >> 16780542

Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update.

M Maloo1, P Abt, R Kashyap, D Younan, M Zand, M Orloff, A Jain, A Pentland, G Scott, A Bozorgzadeh.   

Abstract

Nephrogenic systemic fibrosis (NSF) is a recently characterized systemic fibrosing disorder developing in the setting of renal insufficiency. NSF's rapidly progressive nature resulting in disability within weeks of onset makes early diagnosis important. Two reports of NSF after liver transplantation are known of. We present three cases of NSF developing within a few months after liver transplantation and review the current literature. Loss of regulatory control of the circulating fibrocyte, its aberrant recruitment, in a milieu of renal failure and a recent vascular procedure appear important in its development. Known current therapies lack consistent efficacy. Only an improvement in renal function has the greatest likelihood of NSF's resolution. Delayed recognition may pose a significant barrier to functional recovery in the ubiquitously deconditioned liver transplant patient. Early recognition and implementation of aggressive physical therapy appear to have the greatest impact on halting its progression.

Entities:  

Mesh:

Year:  2006        PMID: 16780542     DOI: 10.1111/j.1600-6143.2006.01420.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  13 in total

1.  [Nephrogenic systemic fibrosis. Medical detective work in the 21st century].

Authors:  B Manger
Journal:  Z Rheumatol       Date:  2007-10       Impact factor: 1.372

Review 2.  Nephrogenic systemic fibrosis in liver disease: a systematic review.

Authors:  Sameer M Mazhar; Masoud Shiehmorteza; Chad A Kohl; Michael S Middleton; Claude B Sirlin
Journal:  J Magn Reson Imaging       Date:  2009-12       Impact factor: 4.813

3.  Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases.

Authors:  Javier Perez-Rodriguez; Shenghan Lai; Benjamin D Ehst; Derek M Fine; David A Bluemke
Journal:  Radiology       Date:  2009-02       Impact factor: 11.105

4.  Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging.

Authors:  Constantina Chrysochou; Albert Power; Aladdin E Shurrab; Sayed Husain; Steven Moser; James Lay; Alan D Salama; Philip A Kalra
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-21       Impact factor: 8.237

Review 5.  Nephrogenic systemic fibrosis.

Authors:  Diego R Martin
Journal:  Pediatr Radiol       Date:  2007-12-11

Review 6.  Pathophysiology of gadolinium-associated systemic fibrosis.

Authors:  Brent Wagner; Viktor Drel; Yves Gorin
Journal:  Am J Physiol Renal Physiol       Date:  2016-05-04

Review 7.  Nephrogenic systemic fibrosis: an epidemic of gadolinium toxicity.

Authors:  Derrick J Todd; Jonathan Kay
Journal:  Curr Rheumatol Rep       Date:  2008-07       Impact factor: 4.592

Review 8.  Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines.

Authors:  Henrik S Thomsen; Sameh K Morcos; Torsten Almén; Marie-France Bellin; Michele Bertolotto; Georg Bongartz; Olivier Clement; Peter Leander; Gertraud Heinz-Peer; Peter Reimer; Fulvio Stacul; Aart van der Molen; Judith A W Webb
Journal:  Eur Radiol       Date:  2012-08-04       Impact factor: 5.315

Review 9.  Nephrogenic systemic fibrosis: chronic imaging findings and review of the medical literature.

Authors:  Jeffrey P Weigle; Dale R Broome
Journal:  Skeletal Radiol       Date:  2008-03-07       Impact factor: 2.199

10.  ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis.

Authors:  Henrik S Thomsen
Journal:  Eur Radiol       Date:  2007-10       Impact factor: 7.034

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.